Mitoxantrone: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Chemotherapy of Cancer

Drugs

Volumn 41, Issue 3, 1991, Pages 400-449

  Faulds, Diana ^a   Balfour, Julia A ^a   Chrisp, Paul ^a   Langtry, Heather D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DIAZEPAM; DOXORUBICIN; FLUOROURACIL; LUCANTHONE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NITROXAZEPINE; THIOTEPA; VERAPAMIL; VINCRISTINE;

ANIMAL CELL; ANIMAL MODEL; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; DNA SYNTHESIS; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; REVIEW; STOMATITIS; TUMOR CELL; ANIMAL; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; NEOPLASM;

ANIMALIA; MURINAE;

ANIMAL; COMPARATIVE STUDY; HUMAN; MITOXANTRONE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0026127460     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199141030-00007     Document Type: Article

References (470)

1. Phase II trial of mitoxantrone in head and neck cancer
2. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study
3. Additive activity of mitoxantrone and doxorubicin in vitro against human breast cancer
4. Disposition of mitoxantrone in cancer patients
5. Endotoxin and double stranded RNA render macrophages cytotoxic
6. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia
7. Radiotherapy with concurrent administration of mitoxantrone in patients with thyroid carcinoma. Abstract 9
8. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study
9. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer
10. Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone
11. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)
12. Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound
13. Effects of mitoxantrone and doxorubicin on energy metabolism of the rat heart
14. Mitoxantrone: an active agent in refractory non-Hodkin’s lymphomas
15. In vitro and in vivo responses of a murine transitional cell carcinoma to doxorubicin, mitoxantrone and aclacinomycin-A
16. A phase II study of epirubicin and mitoxantrone in advanced hepatobiliary and pancreatic carcinoma. Abstract
17. Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone
18. Pharmacokinetics of mitoxantrone in man and laboratory animals
19. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines
20. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update
21. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma
22. Mitoxantrone for refractory and relapsed acute leukemia
23. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine
24. The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer
25. Mitoxantrone, methotrexate, and 5-flourouracil combination chemotherapy as first-line treatment in stage IV breast cancer
26. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer
27. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia
28. Escalating dose regimen of intraperitoneal mitoxantrone: phase I study — clinical and pharmacokinetic evaluation
29. Phase-I study of intraperitoneal mitoxantrone — clinical and pharmacokinetic evaluation
30. Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma
31. Early clinical trials of mitoxantrone
32. Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity
33. Phase II trial of mitoxantrone in advanced colorectal cancer
34. Comparative molecular pharmacology in leukemic LI210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene
35. Mitoxantrone as first-salvage chemotherapy in relapsed breast cancer
36. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia
37. Treatment of RAEB- t with intensive chemotherapy and GM-CSF
38. Breast cancer. Advances in management
39. Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas
40. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin’s lymphoma: an interim report comparing efficacy and toxicity
41. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group Study
42. Lokalisierte neutrophile ekkrine Hidradenitis unter Mitoxantron: eine typische Zytostatikane-benwirkung
43. Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity
44. Membrane lipid alteration: effect on cellular uptake of mitoxantrone
45. Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?
46. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer
47. Continuous infusion (CI) mitoxantrone (MIT) in acute leukemia. Abstract 835
48. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells
49. Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study
50. Phase II trial of mitoxantrone in non-Hodgkin’s lymphoma. Abstract 747
51. Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography
52. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin
53. Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture
54. Comparison of anti-neoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics
55. Identification of human urinary mitoxantrone metabolites
56. 14 C-mitoxantrone in the rat following different intravenous doses and characteristics of drug-related material in the bile. Abstract 354
57. Impiego del mitoxantrone nella terapia dei linfomi non-Hodkin: risultati di uno studio in fase II in monochemioterapia o in associazione. Abstract 310
58. Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil
59. Mitoxantrone use in breast cancer patients with elevated bilirubin
60. A comparative trial of C-Novantrone OP(CNOP) vs C-Adriamycin OP(CHOP) in the treatment of stage II–IV malignant lymphoma — the preliminary report [in Chinese]
61. Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group Phase II protocols
62. Current status of chemotherapy of breast cancer
63. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene
64. Protein associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenedione (DHAD), NSC-301739, in mouse LI210 leukemia cells. Abstract 1111
65. A phase II study of mitozantrone in advanced carcinoma of the ovary
66. Mitoxantrone in advanced breast cancer — a phase II study with special attention to cardiotoxicity
67. Mitoxantrone in refractory nonHodgkin’s lymphoma. A Southwest Oncology Group study
68. Mitoxantrone hydrochloride in lymphoma
69. Combinazione di mitoxantrone ifosfamide, methotrexate (MIM) nel salmataggio dei linfomi non Hodgkin. Abstract 313
70. Mitoxantrone in mono e polichemioterapia nei linfomi non- Hodgkin (LNH) dell’adulto ricadulti o refrattari. Rapporto del NHLCSG. Abstract 314
71. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents
72. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients
73. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: a Southwest Oncology Group study
74. Mitoxantrone affects topoisomerase activities in human breast cancer cells
75. Clinical safety and tolerance of mitoxantrone
76. Mitoxantrone (M) and vinblastine (V) in the treatment of advanced breast cancer
77. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone
78. Development and characterization of a new drug resistant human multiple myeloma cell line. Abstract 766
79. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group Phase II Trial
80. Phase II trial of mitoxantrone in advanced primary liver cancer: a cancer and leukemia group B study
81. Arterielle regionale Chemotherapie fortgeschrittener mammakarzinome
82. In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine
83. An EORTC Phase II study of mitoxantrone in solid tumours and lymphomas
84. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line
85. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma
86. Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group trial
87. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group trial
88. Mitozantrone-induced asteatosis. Correspondence
89. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin
90. Mitoxantrone (MXT) in monochemioterapia (mono CT) nel carcinoma polmonare avanzato non a piccole cellule (NSCLC): studio di fase II. Abstract 265
91. A working formulation of non-Hodgkin’s lymphomas: background, recommendations, histological criteria, and relationship to other classifications
92. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics. Mitoxantrone, bisantrene, 4′-(9-acridinylamino)-methanesulfon-m-anisidide and neocarzinostatin
93. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone
94. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro
95. Comment on mitoxantrone
96. Cytogenetic analysis of bone marrow of rats treated with mitoxantrone hydrochloride, an antineoplastic agent. Abstract 134
97. Biologic and biochemical effects of mitoxantrone
98. Editorial. Multidrug resistance in cancer. Lancet 2: 1075–1076, 1989
99. Intracavitary treatment with mitoxantrone
100. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia
101. Mitoxantrone in the treatment of relapsed and refractory acute leukemia
102. Klinische Pharmacokoiogie von Mitoxantron bei Patienten mit Mammakarzinom und Leukämien
103. Mitoxantrone metabolism in the isolated perfused rat liver
104. Clinical pharmacology of mitoxantrone
105. Pharmacokinetics and metabolism of mitoxantrone: a review
106. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer
107. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study
108. Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group trial
109. Phase II trial of mitoxantrone in refractory acute leukemia
110. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study
111. Residiv eller behandlingsresistens a.v akutt myelogen leukemi. Effekt av mitoksantron og cytosin arabinosid
112. Phase II trial of mitoxantrone in patients with primary liver cancer
113. Hematological toxicity: experience with anthracyclines and anthracenes
114. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG Study
115. Efficacite et toxicile de la mitoxantrone par voie intrapleurale: a propos de 18 cas de metastases pleurales de cancer du sein
116. Selective immunomodulaion by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function
117. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice
118. Comparison of free radical generation by doxorubicin and mitozantrone in MCF-7 human breast cancer cells
119. Oxidative activation of the antitumour agent mitozantrone
120. Chemoterapia del microcitoma con cisplatino (C) + mitoxantrone (M) e etoposide (E) + ifosfamide (I) alternati risultati preliminari di eno studio in fase II. Abstract 248
121. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer
122. Mitoxantrone in the treatment of patients with non-Hodgkin’s lymphoma
123. Cardiac events in phase II trials with mitoxantrone
124. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture
125. Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells
126. DNA-binding specificity and RNA polymerase inhibitory activity of bis-(aminoalkyl)anthraquinones and bis(methylthio)vinyl-quinolinium iodides
127. Effects of mitoxantrone and bisantrene on platelet aggregation and prostaglandin/thromboxane biosynthesis in vitro
128. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer
129. Intra-peritoneal mitoxantrone via temporary catheter in patients with ovarian cancer: toxicity and feasibility evaluation
130. Proposals for the classification of the acute leukaemias
131. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics
132. A phase II study of mitoxantrone in advanced head and neck cancer and advanced breast cancer. Abstract
133. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group trial
134. Mitoxantrone in malignant lymphoma
135. Mitoxantrone cardiotoxicity: results from Southeastern Cancer Study Group
136. Multidrug resistance
137. Phase II trial of mitoxantrone (NVT) and cyclophosphamide (CTX) in advanced breast cancer. Abstract 128
138. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro
139. Phase II trial of mitoxantrone in advanced gastric cancer
140. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Abstract 537P
141. Comparative studies on the antioxidant properties of mitoxantrone, ametantrone and bisantrene. Abstract 876
142. Human central nervous system and plasma pharmacology of mitoxantrone
143. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone
144. Hypomagnesaemia and hypocalcaemia after treatment with mitoxantrone
145. A comparative randomised study of mitoxantrone and doxorubicin combination chemotherapy in advanced breast cancer. Abstract 347
146. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin’s lymphomas
147. Warning against use of intrathecal mitoxantrone. Correspondence
148. Comparison of toxicity of mitozantrone and doxorubicin when used in combination with vincristine and prednisolone for advanced breast cancer. Abstract
149. High activity of mitoxantrone in previously untreated low-grade lymphomas
150. Multi-drug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression
151. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer
152. Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer
153. Assessment of response to therapy in advanced breast cancer
154. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer
155. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine
156. Effect of high dose mitozantrone with Cronassial on the Lewis lung carcinoma and L1210leukaemia
157. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations
158. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
159. Breast cancer
160. Effect of temperature on the cytotoxicity on vindesine, amsacrine, and mitoxantrone
161. B lymphocyte effects of mitoxantrone. Abstract 14
162. Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance
163. Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results
164. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S- HAM) indicating a high antileükemic activity in refractory acute leukemias
165. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)
166. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia
167. Treatment of refractory Hodgkin’s disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group
168. Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group study
169. Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group study
170. Mitoxantrone in epithelial carcinoma of the ovary: a Southwest Oncology Group Study
171. Resistant multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP-regime). Correspondence
172. Mitoxantrone combined with high dose cytarabine for refractory non-Hodgkin’s lymphoma. Effects of recombinant GM-CSF. Abstract 237
173. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin’s lymphoma
174. Mitoxantrone/high dose ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. A pilot study
175. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma
176. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia — an active and well-tolerated regimen
177. Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells
178. Klinische Erfahrungen mit der intraarteriellen, angiographisch gesteuerten Chemotherapie von Lebermetastasen
179. Mitoxantrone, cyclophosphamide and 5-flourouracil in the treatment of hormonally unresponsive metastatic breast cancer
180. Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy
181. Plasma kinetics of mitoxantrone in leukemic patients
182. Anthracycline cardiomyopathy: predictive value of animal models
183. Antitumour efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice
184. Preclinical toxicology studies on mitoxantrone and bisantrene
185. Enhancement of the antiviral activity of poly r(A-U) by ametantrone and mitoxantrone
186. Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines
187. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)
188. Experimental antitumor activity of aminoanthraquinones
189. Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma
190. The human tumor clonogenic assay in human breast cancer
191. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells
192. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia
193. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia
194. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
195. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside
196. Failure (and danger) of mitozantrone in AIDS-related Kaposi’s sarcoma. Correspondence
197. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Abstract 539P
198. Interactions of antitumor agents ametantrone and mitoxantrone (Novatrone) with double-stranded DNA
199. Interactions of a new antitumor agent, l,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9, 10-anthracenedione, with nucleic acids
200. Weekly mitoxantrone therapy of Hodgkin’s disease, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia, A Southeastern Cancer Study Group trial
201. Mitoxantrone and ametantrone inhibit hydroperoxide-dependent initiation and propagation reactions in fatty acid peroxidation
202. Local tissue damage as a result of extravasation of mitozantrone. Correspondence
203. Mitoxantrone-containing combination chemotherapy for patients with non-Hodgkin’s lymphoma
204. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group
205. Chemotherapie hochmalings Schilddrusentumore
206. Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone
207. Survival following an extremely high-dose of mitoxantrone in a 73-year-old female with small cell bronchial carcinoma. Correspondence
208. Possible benefits of hyperthermia to chemotherapy
209. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial
210. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM
211. Treatment with locally applied mitoxantrone
212. Mitoxantrone induced hyperpigmentation
213. Phase 11 study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection
214. Paraplegia after intrathecal mitozantrone. Correspondence
215. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma
216. Mitoxantrone as a first-line treatment of advanced breast cancer
217. A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol
218. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia
219. Therapeutic synergism (TS) of N-(4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide (m-AMSA) or l,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione (DiOHA) plus cis-diamminedichloroplatinum (cis-DDPt) against P388/ 0 leukemia. Abstract 1086
220. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone
221. Population pharmacokinetics of mitoxantrone performed by a NONMEM method
222. Phase II study of mitoxantrone in epithelial ovarian cancer
223. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer
224. Efficacy and toxicity of single agent chemotherapy in advanced breast carcinomas. Abstract
225. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia
226. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial
227. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients
228. Mitoxantrone: potential for use in intensive therapy
229. Mitoxantrone zur Erstbehandlung des metastasierten Mammakarzinoms
230. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast
231. An Israeli National Study. Mitoxantrone, methotrexate, 5-flourouracil versus cyclophosphamide, methotrexate, 5-flourouracil as first line therapy in metastatic breast cancer. Abstract 175
232. A phase II study of mitoxantrone in advanced gastric cancer
233. Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group Pilot Study
234. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues
235. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone
236. Mitoxantrone treatment in advanced breast cancer
237. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia
238. Pharmacokinetics of mitoxantrone intraperitoneal. Abstract 694
239. Ifosfamide e mitoxantrone nella terapia di salvataggio dei linfomi non-hodgkin (NHL). Abstract 324
240. High field H-NMR analysis of the 1: 1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]
241. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy
242. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids
243. Pharmacological disposition of 1,4-dihydroxy-5,8-bis([2-[(2-hydroxymethyl)amino]ethyl]amino)-9,10-anthracenedione dihydrochloride in the dog
244. Suppression of acute and relapsing experimental allergic ericephalomyelitis with mitoxantrone
245. Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems
246. Interactions of hyperthermia and chemotherapy in animals
247. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer
248. A phase II study of mitoxantrone in acute leukemia
249. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck
250. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck
251. Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study
252. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia
253. Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia
254. Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells
255. Kombinationstherapie des metastasierten Mammakarzinoms mit Mitoxantron, Cyclophosphamid und 5-Fluorouracil
256. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy
257. Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation
258. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer: a study of short-term response rate
259. Mitoxantrone in the treatment of relapsed and refractory acute leukemia
260. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen
261. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study
262. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study
263. Malignant diseases
264. High-dose cyclophosphamide or melphalan with excalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors
265. Die isolierte Beckenperfusion (IPP) zur Behandlung primär inoperabler Beckentumaren. Klinische une pharmakokinetische Ergebnisse
266. Antitumor agents. I. l,4-bis[(aminoalkyl)amino]-9,10-anthracenediones
267. Intrapleurale Applikation von Mitoxantron zur Behandlung ausgedehnter Pleuraergüsse bei metastasiertem Mamma-Ca
268. Intrapleural mitoxantrone for treatment of malignant pleural effusion in metastatic breast cancer. Abstract 132
269. Intrapleurale Instillation von Mitoxantron zur Palliativ-Therapie maligner Pleuraergüsse
270. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group
271. Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group
272. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A Gynecologic Oncology Group study
273. Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. A phase II study of the Gynecologic Oncology Group
274. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group
275. DNA binding, cardiac Superoxide production and cytotoxicity of daunomycin analogs
276. A comparison of mitoxantrone and doxorubicin in breast cancer
277. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide
278. Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices
279. Sister-chromatid exchange and chromosomal aberrations by DHAQ and related anthraquinone derivatives in Chinese hamster ovary cells
280. Cellular uptake and inhibition of DNA synthesis by dihydroxyanthraquinone and two analogues
281. Pharmacokinetic studies on mitozantrone in prolonged continuous infusion regimens. Abstract
282. Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancer
283. Mitoxantrone: propensity for free radical formation and lipid peroxidation — implications for cardiotoxicity
284. Mitozantrone (M) and prednimustine (P) in advanced breast cancer (BC). Abstract
285. Diffuse non-Hodgkin’s lymphoma
286. Salvage chemotherapy for non-Hodgkin’s lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone
287. Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect)
288. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells
289. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer
290. Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 1210 and P 388 leukemia
291. Dati prelinari sull’attivatá in vitro dell’a2r IFN e del mitoxantrone su linee cellulane tumorali umane resistenti alia doxorubicina. Abstract 465
292. Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma
293. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia
294. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia
295. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia
296. Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia
297. Il mitoxantrone nel trattomento deU’epatocarcinoma inoperable. Abstract 93
298. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer
299. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig
300. Mitoxantrone extravasation injury
301. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD). Correspondence
302. Mechanism of DNA-binding of some aminoalkylamino-derivatives of anthraquinone and naphthacenequinone
303. Mitoxantrone
304. Inhibition of angiotensin by the anti-neoplastic agents mitoxantrone and bisantrene
305. Mitoxantrone: an overview of safety and toxicity
306. Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study
307. Mitoxantrone in relapsed and refractory acute leukemia
308. Mitoxantrone in malignant melanoma
309. Treatment of metastatic sarcomas with mitoxantrone
310. A phase II study of mitoxantrone in advanced breast cancer
311. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin’s lymphoma
312. Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas
313. Mitoxantrone: progress in a phase II trial in Sydney, Australia. Abstract
314. l4 C-labeled drug
315. Reduced mitoxantrone contents in a mitoxantrone-resistant gastric carcinoma cell line unrelated to the multidrug-resistance phenotype. Abstract 162
316. Competitive fluorescence polarization study of the binding of l,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl) amino]ethyl]amino] 9-10-anthracenedione to DNA
317. Suppression of experimental allergic encephalomyelitis by mitoxantrone
318. Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML im Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85
319. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line
320. Mitoxantrone — a useful palliative therapy in advanced breast cancer
321. Comparison of the interaction of antineoplastic aminoanthraquinone analogs with DNA using competitive fluorescence polarization
322. Mitoxantrone in advanced solid tumors: status of the art and perspectives
323. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
324. Mitoxantrone sensitivity of human hematopoietic cell lines
325. Direct and indirect clastogenic activity of anthracenedione in Chinese hamster ovary cells
326. Mitoxantrone therapy of advanced adenocarcinoma of the endometrium: a phase II trial
327. Growth and ultrastructural responses of T-47D human breast tumor cells to treatment with mitoxantrone
328. Influence of mitoxantrone on nucleic acid synthesis on the T-47D breast tumor cell line
329. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay
330. Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias
331. Phase II study of mitoxantrone in patients with hematological malignancy
332. Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia
333. High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia
334. Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies
335. Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells
336. Pharmacology of mitoxantrone in cancer patients
337. Therapeutic activity of mitoxantrone and ametantrone against murine tumors
338. Establishment of cross-resistance profiles for new agents
339. Phase II evaluation of mitoxantrone in advanced non-anaplastic thyroid cancer
340. Mitoxantrone — an immunosuppressive agent potentially useful in the organ transplantation. Abstract 7431
341. 5-Fluorouracil plus mitoxantrone in the treatment of advanced colorectal cancer initial experiences. Abstract 145
342. Phase II trial of mitoxantrone (DHAD NSC 301739) in blastic phase in chronic myelogenous leukemia (B-CML). Abstract 558
343. Mitoxantrone and hepatic toxicity. Correspondence
344. Mitoxantrone: a new anticancer drug with significant clinical activity
345. Possible mitoxantrone-induced amenorrhea
346. Intensive single-agent mitoxantrone for metastatic breast cancer
347. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection
348. Accidental overdose of mitoxantrone in three patients
349. Mitozantrone or doxorubicin with vincristine and cyclophosphamide (VNC vs VAC) in the treatment of advanced breast cancer. Abstract
350. Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats
351. Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project
352. Mitoxantrone (novantrone): a review of experimental and early clinical studies
353. Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer
354. Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European Collaborative Study
355. The clinical pharmacology of mitozantrone
356. Full dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma: a feasibility study using a mitoxantrone containing regimen
357. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologie and ultrastructural pathology
358. Human autopsy tissue concentrations of mitoxantrone
359. Combined mitoxantrone plus doxorubicin in the treatment of breast cancer
360. Mitoxantrone: an active new agent in the treatment of advanced breast cancer
361. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone
362. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours
363. Effect of l,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino) ethyl amino)-9,10-anthracenedione(dihydroxyanthraquinone) on the replication of Simian virus 40 chromosome
364. Phase II study of mitoxantrone in patients with non-small cell lung cancer
365. Allergic reactions to mitoxantrone. Correspondence
366. Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study
367. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study
368. Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital
369. Intercalative anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
370. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
371. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin
372. A phase II study of mitozantrone in advanced breast cancer. Abstract
373. Anthracycline-carboplatin combination in metastatic breast cancer
374. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers
375. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
376. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns
377. Acute myocardial effects of mitoxantrone in the rabbit
378. Phase I trial of mitoxantrone in children
379. Functional characteristics of human heart after mitoxantrone
380. Cardiac evaluation of mitoxantrone
381. Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia-individualized chemotherapy
382. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy
383. Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-Urinary Tract Cancer Cooperative Group
384. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group
385. Mitoxantrone in advanced and/or recurrent endometrial carcinoma. Correspondence
386. Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy
387. Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study
388. Phase II evaluation of mitoxantrone in patients with advanced nasopharyngeal carcinoma
389. Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone
390. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group study
391. Activity of mitoxantrone in a human tumor cloning system
392. Phase I clinical investigation of l,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione
393. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone
394. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin’s lymphoma
395. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia
396. Adriamycin-induced compaction of isolated chromatin
397. The inhibitory effect of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride (CL 232315; NSC 301739D) on dividing and non dividing cells in vitro Abstract 49
398. Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro
399. Activity of a novel anthracenedione, l,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione dihydrochloride, against experimental tumors in mice
400. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
401. Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone
402. Inhibition of the induction of alloreactivity with mitoxantrone
403. CMPP chemotherapy for intermediate and high grade non-Hodgkin’s lymphoma in the elderly. Abstract
404. New combination chemotherapy programme for bladder cancer
405. Recent advances in the design of anticancer chemotherapy
406. Genotoxicity of the new potent cancer chemotherapeutic agent mitoxantrone. Abstract 109
407. A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck
408. Pharmacokinetics of mitoxantrone in patients with metastatic breast cancer (MBC) with liver metastases. Abstract 115
409. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group
410. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial
411. First-line mitoxantrone chemotherapy for advanced breast cancer
412. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases
413. Treatment of acute leukemia with “MB-triple V” therapy — a comparative study of “MB-triple V” therapy and B-triple V therapy
414. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer
415. Phase II trial of mitoxantrone in patients with hepatocellular carcinoma
416. Aspekte der kombinierten Radio- und Chemotherapie bei fortgeschrittenen Kopf-Hals-Tumoren
417. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats